We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Microsoft (MSFT - Free Report) has a great track record of beating on earnings, so no one was surprised when the company did it again in July. It posted a strong fiscal fourth quarter with Commercial Cloud revenue up 39%, led by Azure up 64%. Office 365 now has 34.8 million subscribers and LinkedIn saw record engagement in the quarter. The company is only trading with a forward P/E of 26. It’s a Zacks Rank #2 (Buy) stock. [In full disclosure, Tracey owns shares of Microsoft in her personal portfolio.]
Cintas (CTAS - Free Report) beat on the fourth quarter and gave guidance for fiscal 2020 above the Zacks Consensus as the uniform rental business remains strong. It saw strength in healthcare, education and government. It has now posted 9 consecutive years of mid-single digit revenue growth. That’s impressive. Cintas shares are also breaking out to new multi-year highs on the news. It’s a Zacks Rank #2 (Buy) stock.
Should these two companies be on your investing short list? Find out in this week’s video.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Top Stock Picks for the Week of July 22, 2019
Microsoft (MSFT - Free Report) has a great track record of beating on earnings, so no one was surprised when the company did it again in July. It posted a strong fiscal fourth quarter with Commercial Cloud revenue up 39%, led by Azure up 64%. Office 365 now has 34.8 million subscribers and LinkedIn saw record engagement in the quarter. The company is only trading with a forward P/E of 26. It’s a Zacks Rank #2 (Buy) stock. [In full disclosure, Tracey owns shares of Microsoft in her personal portfolio.]
Cintas (CTAS - Free Report) beat on the fourth quarter and gave guidance for fiscal 2020 above the Zacks Consensus as the uniform rental business remains strong. It saw strength in healthcare, education and government. It has now posted 9 consecutive years of mid-single digit revenue growth. That’s impressive. Cintas shares are also breaking out to new multi-year highs on the news. It’s a Zacks Rank #2 (Buy) stock.
Should these two companies be on your investing short list? Find out in this week’s video.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>